Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib-Reference-Cited by-同舟云学术

Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib

Published:2016-10-28 Issue:12 Volume:16 Page:1303-1309
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Kawalec Pawel¹,Malinowska-Lipień Iwona²,Brzostek Tomasz²,Kózka Maria³

Affiliation:

1. Department of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

2. Department of Internal and Community Nursing, Institute of Nursing and Midwifery, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

3. Department Clinical Nursing, Institute of Nursing and Midwifery, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2016.1247697

Reference19 articles.

1. Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients

2. THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis

3. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas

4. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the significance of quinoline containing compounds as potent VEGFR-2 inhibitors for cancer therapy;Medicinal Chemistry Research;2024-06-27

2. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis;Frontiers in Pharmacology;2022-08-26

3. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer;Frontiers in Endocrinology;2021-07-15

4. Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm;Critical Reviews in Oncology/Hematology;2021-06

5. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy;Biomolecules;2020-12-15